Navigation Links
Boston Scientific Announces Schedule for EuroPcr 2007

Company to release broad range of clinical data on leading drug-eluting stent portfolio

NATICK, Mass., May 15, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events and press announcements at the annual Paris Course on Revascularization (EuroPCR), which will runs from May 22 to 25 in Barcelona, Spain.

"We will be announcing new data from several of our clinical trials and registries, adding to the knowledge base for treating coronary artery disease," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "Pooled data from our ARRIVE registries will shed light on key predictors for stent thrombosis in real-world DES use. Additional data will provide insight into the performance of our market-leading TAXUS(R) paclitaxel-eluting stent systems as well as our new everolimus-based PROMUS(TM) (XIENCE(TM) V) stent system, reinforcing Boston Scientific's role as the only company offering two distinct drug-eluting stent platforms."

    Schedule of Events (all times are local Barcelona)


    Tuesday, May 22


    * The Great Debate on DES.  The Company will host a symposium entitled

      "The Great Debate on Coronary Drug-Eluting Stents," chaired by Jean

      Marco, M.D., and Steven Nissen, M.D., from 1:30 - 3:15 p.m. in Room 1 of

      The Centre de Convencions Internacional de Barcelona.  Experts will

      debate and answer questions from interventional cardiologists related to

      coronary drug-eluting stent usage in daily practice.


    * TAXUS VI four-year data.  At 5:01 p.m., Professor Eberhard Grube, M.D.,

      will present four-year results from the TAXUS VI trial in a late-

      breaking session.  This randomized, double-blind trial is designed to

      assess the safety and efficacy of a moderate-release (non-

      commercialized) formulation paclitaxel-eluting stent versus a bare metal

      stent control group.  Data will be presented on examined s
ubgroups

      including patients with long lesions, overlapping stents, and small

      vessels.  The Company plans to issue a press release at this time.


    * Predictors of Stent Thrombosis in real-world use.  Two-year results from

      the ARRIVE 1 registry and pooled one-year data from ARRIVE 1 & 2 will be

      presented by David Dobies, M.D., F.A.C.C., at 5:07 p.m. in a late-

      breaking session.  Data will focus on predictors of stent thrombosis in

      real-world patients treated with drug-eluting stents.  The Company plans

      to issue a press release at this time.


    * SYNTAX Trial update.  In a late-breaking trial session at 5:46 p.m.,

      Patrick Serruys, M.D., will present final enrollment numbers for SYNTAX,

      a randomized, controlled clinical trial with nested registries designed

      to compare 12-month MACCE rates between the company's TAXUS(R)

      Express2(TM) paclitaxel-eluting coronary stent system and coronary

      artery bypass graft (CABG) treatment.  The trial will study patients

      with three vessel disease and/or left main disease, a level of patient

      and lesion complexity not examined in prior DES studies.  SYNTAX

      recently completed enrollment of more than 3,000 patients at 85 sites in

      Europe and the United States.


    * SPIRIT Trial Results -- XIENCE(TM) V (PROMUS(TM)) Stent and TAXUS Stent.

      At 6:17 p.m., results from Abbott's SPIRIT I, II and III clinical trials

      will be presented by Gregg W. Stone, M.D., at a late-breaking trial

      session.  In addition to a three-year update on the SPIRIT FIRST trial

      results, Dr. Stone will provide a meta-analysis of data from patients in

      SPIRIT II and SPIRIT III treated with the XIENCE V (PROMUS) Stent or the

      TAXUS Express2 Stent.  The SPIRIT family of trials is designed to

      evaluate the XIENCE V Everolimus-Eluting Coronary Stent System,

      manufactured and sold by Abbott, and also marketed
 by Boston Scientific

      as the PROMUS Stent, versus the TAXUS Express2 Paclitaxel-Eluting

      Coronary Stent System in the treatment of coronary artery disease.  The

      Company plans to issue a press release at this time.


    Wednesday, May 23


    * Focus Session on DES in diabetics(1).  The Company will sponsor a focus

      session entitled "Optimizing coronary drug-eluting stent results in

      diabetics," chaired by Prof. Sigmund Silber, M.D., from 2:00 - 4:30 p.m.

      in Room 9.  In addition to a live case transmission, experts will review

      practical techniques and strategies for dealing with PCI in diabetic

      patients.


      (1) The safety and effectiveness of the TAXUS Express(TM) Stent have not

          been established in patients with diabetes.


    Thursday, May 24


    * Focus Session on carotid artery stenting.  The Company will sponsor a

      focus session entitled "Clinical and technical considerations for daily

      carotid artery stenting practice," chaired by Nick Hopkins, M.D., from

      2:00 - 4:30 p.m. in Room 6.  In addition to a live case transmission,

      experts will review key clinical data and technology selection criteria

      as well as basic neurorescue techniques.


    * Analyst Meeting.  From 9:00-10:00 a.m., the Company will host an analyst

      meeting at the Hotel Hilton Diagonal Mar.  The meeting is open to the

      media.  Registration is required for admittance.  This meeting is being

      webcast and can be accessed at Boston Scientific's website,

      www.bostonscientific.com.  Please visit the website for details on how

      to access the webcast.  A replay of the webcast will be archived and

      available in the Webcast and Archives section of the Investor Relations

      site at www.bostonscientific.com.

Boston Scientific will present its latest innovations at booth D08 in the Exhibit Hall, including its drug-eluting stent program and peripheral treatment options. Additionally, the Company will introduce a software update for the iLab(TM) Ultrasound Imaging System, which further enhances compatibility and connectivity of iLab's IVUS images with Picture and Communication Systems (PACS) at cardiac catheterization labs.

PROMUS, TAXUS, Express and Express2 are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott. The PROMUS Stent is not approved for sale in the U.S.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.


    CONTACT:  Paul Donovan

              508-650-8541 (office)

              508-667-5165 (mobile)

              Media Relations

              Boston Scientific Corporation


              Dan Brennan

              508-650-8538 (office)

              617-459-2703 (mobile)

              Investor Relations

              Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541 (office),+1-508-667-5165 (mobile), or Dan Brennan, Investor Relations,+1-508-650-8538 (office), +1-617-459-2703 (mobile), both of BostonScientific Corporation

Web site: http://www.bostonscientific.com/

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - ... Medical Devices sector report, "Aesthetic Devices - Medical Devices ... currently in pipeline stage. This report ... and primary research by GlobalData,s team of industry experts. ... removed or altered based on the availability and relevance ...
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016  Neurocrine ... the Company will report its fourth quarter and year-end ...  February 11, 2016.  Neurocrine will then host a live ... and provide a Company update Thursday afternoon, February 11, ... Time). http://www.neurocrine.com . --> http://www.neurocrine.com ...
(Date:2/8/2016)... N.J. , Feb. 8, 2016   GS1 ... healthcare professionals to guide them through GS1 Standards implementation ... Drug Administration (FDA) Unique Device Identification (UDI) rule. ... GS1 US; Beth Gibson , senior director industry ... , industry development director, GS1 US --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now ... country. The AutismOne 2016 Conference, which is being held May 25-29 at the Loews ... elsewhere about helpful interventions and causes of chronic illness in children. , Very recent ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
Breaking Medicine News(10 mins):